跳转至内容
Merck
CN

A6610

Sigma-Aldrich

Anti-ASNS (506-520) antibody produced in rabbit

IgG fraction of antiserum, buffered aqueous solution

别名:

Anti-Asparagine synthetase, Anti-TS11

登录查看公司和协议定价

选择尺寸


关于此项目

UNSPSC代码:
12352203
NACRES:
NA.41
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

rabbit

偶联物

unconjugated

抗体形式

IgG fraction of antiserum

抗体产品类型

primary antibodies

克隆

polyclonal

表单

buffered aqueous solution

分子量

antigen ~64 kDa

种属反应性

human

技术

western blot: 1:500-1:2,000

UniProt登记号

运输

dry ice

储存温度

−20°C

靶向翻译后修饰

unmodified

基因信息

human ... ASNS(440)

一般描述

ASNS is an enzyme that promotes the production of asparagine from aspartate.
Asparagine synthetase (ASNS) deficiencies have been linked to progressive encephalopathy and congenital microcephaly. Furthermore, ASNS has also been analyzed for its role in drug-resistant childhood acute lymphoblastic leukemia (ALL). Rabbit Anti-ASNS (506-520) binds to human ASNS (506-520).

免疫原

synthetic peptide corresponding to amino acids 506-520 of human ASNS

应用

Rabbit Anti-ASNS (506-520) antibody has been used for western blot applications at dilutions of 1:500-1:2,000.
Yale Center for High Throughput Cell Biology IF-tested antibodies. Each antibody is tested by immunofluorescence against HUVEC cells using the Yale HTCB IF protocol. To learn more about us and Yale Center for High Throughput Cell Biology partnership, visit sigma.com/htcb-if.

外形

0.01M 磷酸缓冲盐溶液,pH 7.4,含 15mM 叠氮化钠。

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Philip L Lorenzi et al.
Drug news & perspectives, 22(1), 61-64 (2009-02-12)
L-Asparaginase (L-ASP) is an enzyme drug that has been an asset to leukemia treatment regimens for four decades. Variability in its clinical efficacy, however, has prompted the search for biomarkers capable of distinguishing responders from non-responders. In that regard, the
Nigel G J Richards et al.
Annual review of biochemistry, 75, 629-654 (2006-06-08)
Modern clinical treatments of childhood acute lymphoblastic leukemia (ALL) employ enzyme-based methods for depletion of blood asparagine in combination with standard chemotherapeutic agents. Significant side effects can arise in these protocols and, in many cases, patients develop drug-resistant forms of
Elizabeth K Ruzzo et al.
Neuron, 80(2), 429-441 (2013-10-22)
We analyzed four families that presented with a similar condition characterized by congenital microcephaly, intellectual disability, progressive cerebral atrophy, and intractable seizures. We show that recessive mutations in the ASNS gene are responsible for this syndrome. Two of the identified

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持